A new study conducted by Oracle Health Sciences and Informa Engage/Pharma Intelligence has showed that 62% of drug safety experts prefer using artificial intelligence (AI) for adverse event (AE) processing.
The research found that drug safety teams believe AI can aid in identifying risks early, allow effective management and compliance with regulations in a pharmacovigilance setting. Drug safety teams view AI as a means to achieve this, and have already begun to explore its potential.
Conducted between November and December 2017, the study involved 153 professionals across regulatory affairs, risk management, pharmacovigilance and adverse event case reporting in North America, Europe, Asia Pacific, South America, the Middle East and Africa.
Of the total respondents, 27% have already implemented or plan to use AI for quality assurance, 23% prefer the technologies for follow-up processing and 19% want them for rapid reporting.
Oracle Health Sciences safety product strategy vice-president Bruce Palsulich said: “With the increase in adverse events reported, and the flat growth in resources to manage safety case processing, pharmacovigilance teams are under extreme pressure to do more with less.
“Fortunately, adverse event processing is becoming faster and smarter with the help of AI and the cloud. Both technologies are helping drug safety experts to improve quality and accuracy in the handling of the data they work with, and drive down their reporting costs.”
The study further revealed an industry-wide shift towards cloud-based systems for better security.
Approximately 60% of the respondents stated that they have already implemented cloud-based safety solutions or are planning to move to such platform within two years.